Insurance Pool Formed

WASHINGTON-A group of biotechnology companies have agreed to form a captive insurance plan to help them cope with the rising cost of liability insurance. The captive plan will give participating companies both product liability and directors and officers' coverage, explained Jeffrey Gibbs, associate general counsel for the 175-member Association of Bio technology Companies. It will provide the 24 companies now interested in the plan with an aggregate limit of $2.5 million in liability coverage,

Written bySusan Walton
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WASHINGTON-A group of biotechnology companies have agreed to form a captive insurance plan to help them cope with the rising cost of liability insurance.

The captive plan will give participating companies both product liability and directors and officers' coverage, explained Jeffrey Gibbs, associate general counsel for the 175-member Association of Bio technology Companies. It will provide the 24 companies now interested in the plan with an aggregate limit of $2.5 million in liability coverage, a figure that will rise as more companies join.

The company will be incorporated in Vermont because of favorable tax laws in that state. Partici pants are expected to seek bids for underwriting the plan early next year and will compare them to the cost of self-insurance.

Regardless of the approach chosen, each participating company will pay considerably less than it would for individual coverage, Gibbs estimated. Firms will pay ac cording to the risk posed ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies